Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term AZD0837 vs Vitamin-K antagonists for stroke prevention in atrial fibrillation
2007-001722-27Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atecegatran metoxil in Atrial fibrillation (AFib) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of long-term AZD0837 vs Vitamin-K antagonists and Pharmacokinetics of AZD0837 and its metabolites. Started Jul 2007; status: completed.
02
Drugs
atecegatran metoxil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-001722-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001722-27.